SeaStar Medical Stock (NASDAQ:ICU)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$4.24

52W Range

$2.07 - $13.40

50D Avg

$3.10

200D Avg

$4.82

Market Cap

$11.52M

Avg Vol (3M)

$144.69K

Beta

-1.19

Div Yield

-

ICU Company Profile


SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

19

IPO Date

Mar 18, 2021

Website

ICU Performance


ICU Financial Summary


Dec 25Dec 24Dec 23
Revenue$1.23M$135.00K-
Operating Income$-12.18M$-17.84M$-14.21M
Net Income$-12.15M$-24.83M$-26.23M
EBITDA$-12.18M$-24.58M$-11.14M
Basic EPS$-5.86$-66.30$-302.62
Diluted EPS$-5.86$-66.30$-302.62

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q3 25Nov 13, 25 | 4:30 PM
Q1 25May 14, 25 | 4:30 PM

Peer Comparison


TickerCompany
LNAILunai Bioworks Inc.
MBRXMoleculin Biotech, Inc.
BLRXBioLineRx Ltd.
ATHAAthira Pharma, Inc.
ADTXAditxt, Inc.
APLMApollomics, Inc.
LPTXLeap Therapeutics, Inc.
CTXRCitius Pharmaceuticals, Inc.
AIMDAinos, Inc.
THARTharimmune, Inc.